Journal of Hepatology
Volume 46, Issue 6 , Pages 1143-1148 , June 2007

Genetics in liver diseases

  • Antonello Pietrangelo

      Affiliations

    • Center for Hemochromatosis, University Hospital of Modena, Via del Pozza 71, 41100 Modena, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 05 9422 2714.
    • ,
  • Ronald Oude Elferink

      Affiliations

    • AMC Liver Center, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Jesus Prieto

      Affiliations

    • Department of Medicine, University of Navarra, Pamplona, Spain
    • ,
  • Bruce R. Bacon

      Affiliations

    • Division of Gastroenterology and Hepatology, Saint Louis University, St. Louis, MO, USA

References 

  1. Ferrari F, Foglieni B, Arosio P, Camaschella C, Daraio F, Levi S, et al. Microelectronic DNA chip for hereditary hyperferritinemia cataract syndrome, a model for large-scale analysis of disorders of iron metabolism. Hum Mutat. 2006;27:201–208
  2. Burke W. Genetic testing. N Engl J Med. 2002;347:1867–1875
  3. van Leeuwen DJ, Bernat JL. Ethical, social and legal implications of genetic testing in liver disease. Hepatology. 2006;43:1195–1201
  4. Abiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, Bennett B, et al. The nature and identification of quantitative trait loci: a community’s view. Nat Rev Genet. 2003;4:911–916
  5. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev. 2000;174:160–171
  6. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Santamaria M, Lee DC, et al. Novel role for amphiregulin in protection from liver injury. J Biol Chem. 2005;280:19012–19020
  7. Pauli-Magnus C, Stieger B, Meier Y, Kullak-Ublick GA, Meier PJ. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol. 2005;43:342–357
  8. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489–499
  9. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 2003;37:493–503
  10. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol. 2006;41:209–224
  11. Day CP. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:673–691xi
  12. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis. 2002;6:707–725
  13. Frodsham AJ, Zhang L, Dumpis U, Taib NA, Best S, Durham A, et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci USA. 2006;103:9148–9153
  14. Kato N, Ji G, Wang Y, Baba M, Hoshida Y, Otsuka M, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846–853
  15. Ku NO, Lim JK, Krams SM, Esquivel CO, Keeffe EB, Wright TL, et al. Keratins as susceptibility genes for end-stage liver disease. Gastroenterology. 2005;129:885–893
  16. Pietrangelo A. Hereditary hemochromatosis. Annu Rev Nutr. 2006;26:251–270
  17. Panagiotakaki E, Tzetis M, Manolaki N, Loudianos G, Papatheodorou A, Manesis E, et al. Genotype–phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am J Med Genet A. 2004;131:168–173
  18. Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis. 2004;8:787–805viii
  19. Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol. 2003;38:107–117
  20. Thunell S, Harper P. Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda – suggestions for a handling programme. Scand J Clin Lab Invest. 2000;60:561–579
  21. Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology. 2006;130:908–925
  22. Spirli C, Fiorotto R, Song L, Santos-Sacchi J, Okolicsanyi L, Masier S, et al. Glibenclamide stimulates fluid secretion in rodent cholangiocytes through a cystic fibrosis transmembrane conductance regulator-independent mechanism. Gastroenterology. 2005;129:220–233
  23. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem. 2006;75:295–332
  24. Drenth JP, Martina JA, van de Kerkhof R, Bonifacino JS, Jansen JB. Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med. 2005;11:37–42
  25. Scaglia F, Brunetti-Pierri N, Kleppe S, Marini J, Carter S, Garlick P, et al. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. J Nutr. 2004;134:2775S–2782Sdiscussion 2796S-2797S
  26. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology. 2005;42:514–521
  27. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342–347
  28. Wang l, Hernandez-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology. 2004;126:278–289
  29. Peñuelas I, Mazzolini G, Boán JF, Sangro B, Martı´-Climent J, Ruiz M, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 2005;128:1787–1796

PII: S0168-8278(07)00182-1

doi: 10.1016/j.jhep.2007.03.009

Journal of Hepatology
Volume 46, Issue 6 , Pages 1143-1148 , June 2007

Article Tools